Radioiodination of monoclonal antibodies, proteins and peptides for diagnosis and therapy: A review of standardized, reliable and safe procedures for clinical grade levels kBq to GBq in the Göttingen/Marburg experience

NuklearMedizin

Volumn 41, Issue 2, 2002, Pages 71-79

  Behr, Thomas M ^a   Gotthardt, M ^a   Becker, W ^a   Behe M ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Radioimmunotherapy; Radioiodination

Indexed keywords

EDRECOLOMAB; MONOCLONAL ANTIBODY; PEPTIDE; PROTEIN; RITUXIMAB;

IMMUNOREACTIVITY; ISOTOPE LABELING; MOLECULAR WEIGHT; NUCLEAR MEDICINE; PROTEIN DEGRADATION; QUALITY CONTROL; RADIOIMMUNOTHERAPY; RADIOIODINATION; RELIABILITY; REVIEW;

EID: 0036223858     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1625644     Document Type: Review

References (27)

1. 99mTc-labeled anti-CEA monoclonal antibodies for immunoscintigraphy in colorectal cancer
2. Radioimmunotherapy of solid tumors: A review "Of Mice and Men"
3. 131I-labeled anti-CEA murine IgG monoclonal antibody
4. 131I-labeled CO17-1A in a human colorectal cancer model
5. CD22 is a suitable target molecule for detection and high-dose, myeloablative radioimmunotherapy with the monclonal antibody LL2 in acute lymphatic leukemia and Waldenström's macroglobulinemia
6. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: Preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial
7. Radiolabeled peptides for targeting of cholecystokinin-B/gastrin receptor expressing tumors: From preclinical development to initial clinical results
8. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies
9. Radio-immunotherapy of small volume disease of colorectal cancer metastatic to the liver: Preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study
10. Imaging tumors with peptide-based radioligands
11. 131I-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support: Results of a pilot study
12. 131I-labeled humanized anti-CEA antibody, hMN14
13. 125I-containing acylating agent
14. Protein and cell membrane iodinations with a sparingly soluble chloramide, 1,3,4,6-tetrachloro-3a,6a-diphenyl-glycoluril
15. Scintigraphic detection of insulinomas by [I123]-glucagon-like peptide-1 and its analogon [I123]-exendin4 [Y39] in a rat tumor model
16. Preparation of iodine-131 labelled human growth hormone of high specific activity
17. 131I]anti-B1 (anti-CD20) antibody
18. Determination of the immunoreactive fraction of radio-labeled antibodies by linear extrapolation to binding at infinite antigen excess
19. Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabeling
20. Limitations of the Lindmo method in determining antibody immunoreactivity
21. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support
22. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphoma
23. Treatment of relapsed B cell lymphoma with high-dose radioimmunotherapy and bone marrow transplantation
24. Evaluation of a CDR-grafted (humanized) anti-carcino-embryonic antigen (CEA) monoclonal antibody in preclinical and clinical studies
25. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22
26. Evaluation of a remote radioiodination system for radioimmunotherapy